https://www.selleckchem.com/products/erastin.html Our results showed that 23 (1.91%) snails were positive for T. gondii B1 gene. The genotype of two of the 23 T. gondii amplicons was consistent with ToxoDB Genotype #9. Multiple logistic regression revealed that surface runoff near the sampling site (P = 0.039, odds ratio [OR] = 3.413, 95% confidence interval [CI] 1.07-10.94) and residential water discharge near the sampling site (P = 0.021, OR = 3.990, 95%CI 1.24-12.87) are more likely to be associated with the presence of T. gondii DNA in marine snails. The detection of T. gondii DNA in marine snails in China highlights the potential impact of the anthropogenic activities on marine organisms and the potential foodborne risk posed to humans with such an important terrestrial pathogen.We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including drug repurposing and repositioning, are being tested to treat patients with COVID-19. Researchers have developed several potential vaccine candidates that have shown promise in phase II and III trials. As of 12 November 2020, 164 candidate vaccines are in preclinical evaluation, and 48 vaccines are in clinical evaluation, of which four have cleared phase III trials (Pfizer/BioNTech's BNT162b2, Moderna's mRNA-1273, University of Oxford & AstraZeneca's AZD1222, and Gamaleya's Sputnik V vaccine). Despite the acquisition of a vast body of scientific information, treatment depends only on the clinical management of the disease through supportive care. At the pandemic's 1-year mark, we summarize current